Text Size

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-Small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00372788
First received: September 5, 2006
Last updated: May 13, 2009
Last verified: May 2009
History of Changes
  Purpose

The purpose of this study is to assess the effect and safety of AZD6244(ARRY-142886)versus pemetrexed in the second or third line treatment of advanced Non-Small Cell Lung Cancer. Following baseline assessments, a minimum of 64 patients in approximately 5-6 centers from the US will be treated with either AZD6244 or pemetrexed. Treatment will be continued for as long as patients receive clinical benefit.


Condition Intervention Phase
Non-Small Cell Lung Cancer
 Drug: AZD6244
Drug: Pemetrexed
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-Small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Assess tumor growth [ Time Frame: assessed every 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Assess safety and tolerability of AZD6244 [ Time Frame: assessed at each visit ] [ Designated as safety issue: Yes ]

Enrollment: 88
Study Start Date: August 2006
Study Completion Date: December 2008
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Pemetrexed
 Drug: Pemetrexed
oral
Other Name: Alimta®
Experimental: 2
AZD6244
 Drug: AZD6244
oral vial
Other Name: ARRY-142886

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed with non-small cell lung cancer
  • Previously received one or two chemotherapeutic treatments

Exclusion Criteria:

  • Previous therapy with MEK inhibitor or pemetrexed
  • Any recent surgery, unhealed surgical incision or severe condition such as uncontrolled cardiac disease or chronic gastrointestinal diseases
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00372788

Locations
United States, California
Research Site
Los Angeles, California, United States
United States, Michigan
Research Site
Ann Arbor, Michigan, United States
United States, New York
Research Site
New York, New York, United States
United States, Tennessee
Research Site
Nashville, Tennessee, United States
Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria
Romania
Research Site
Cluj-Napoca, Romania
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Emerging Oncology Medical Science Director, MD AstraZeneca
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00372788     History of Changes
Other Study ID Numbers: D1532C00012
Study First Received: September 5, 2006
Last Updated: May 13, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
NSCLC
Advanced Non-Small Cell Lung Cancer
AZD6244

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
 Pemetrexed
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Antimetabolites, Antineoplastic
Antimetabolites

ClinicalTrials.gov processed this record on May 19, 2013